ddeeper Than Deep: Can ddPCR Predict Successful Imatinib Cessation?
prospective_cohort · Level II
Where this comes from
- Record sourced from PubMed, PMID 31540978.
- Also identified by DOI 10.1158/1078-0432.CCR-19-2270 and PMC identifier 6858959.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
<i>BCR-ABL1</i> transcripts at imatinib cessation were quantified by droplet digital PCR (ddPCR) for 175 patients on the STIM2 trial. Patients with <i>BCR-ABL1</i> transcripts below a defined cutoff had a 12-month molecular recurrence rate of 46% versus 68% for those above the cutoff. Implications of using ddPCR in forecasting successful imatinib cessation are discussed.<i>See related article by Nicolini et al., p. 6606</i>.
Medical subject headings
- Fusion Proteins, bcr-abl
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive